Prime Medicine (NYSE:PRME) Lifted to Sell at upgraded shares of Prime Medicine (NYSE:PRMEGet Rating) to a sell rating in a research report sent to investors on Tuesday.

Prime Medicine Stock Performance

Prime Medicine stock opened at $13.52 on Tuesday. Prime Medicine has a fifty-two week low of $11.07 and a fifty-two week high of $21.73.

Insider Transactions at Prime Medicine

In related news, major shareholder 2019 Gp L.L.C. Gv sold 87,922 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $14.13, for a total value of $1,242,337.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Prime Medicine Company Profile

(Get Rating)

Prime Medicine Inc is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc is based in CAMBRIDGE, Mass.

Recommended Stories

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with's FREE daily email newsletter.